Scholarlink

Background <p>Multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) imposes significant financial burdens on patients. This study aimed to examine the current status of the economic burden of disease in patients with MDR/RR-TB in Lishui City, Zhejiang Province, and to describe the actual implementation status of the diagnosis-and-treatment subsidy policy and explore associations between subsidy indicators and patient treatment outcomes.</p> Methods <p>We conducted a retrospective survey of 117 MDR/RR-TB patients diagnosed and managed in Lishui City from 2017 to 2022. Data on sociodemographic characteristics, diagnosis and treatment processes, medical expenses, and subsidy information were collected and analyzed using questionnaires.</p> Results <p>The median direct medical expenses (DME) for the 117 patients were Chinese yuan (RMB) 65,182.66 (1 RMB = 0.14 USD). The median amount reimbursed by medical insurance was RMB 40,223.33, and the median out-of-pocket (OOP) payments after medical insurance reimbursement were RMB 21,938.82. The median subsidy amount was RMB 14,405.45, resulting in final OOP payments of RMB 8,167.13. Patients using bedaquiline, linezolid, and clofazimine received higher subsidies compared to non-users (<i>P</i> &lt; 0.05). Logistic regression analysis showed that subsidy amounts below RMB 14,405.45 were significantly associated with adverse treatment outcomes (95%CI: 0.046–0.534, OR = 0.157, <i>P</i> = 0.003). The overall treatment success rate was 75.21%.</p> Conclusion <p>MDR/RR-TB patients face a significant economic burden. The findings suggest that the subsidy policy may contribute to reducing out-of-pocket expenditures among MDR/RR-TB patients; however, further studies using stronger analytical designs are needed to evaluate its effectiveness. Optimizing subsidy criteria, raising subsidy levels and streamlining reimbursement procedures may help relieve patient financial stress, yet relevant benefits require verification via high-quality research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Economic burden of MDR/RR-TB and implementation of a treatment subsidy policy in Lishui City, China: a retrospective study following strobe guidelines

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月23日

查看全文
  • Qian Zhu,
  • Guang-Nao Zhou,
  • Jing Guo

摘要

Background

Multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) imposes significant financial burdens on patients. This study aimed to examine the current status of the economic burden of disease in patients with MDR/RR-TB in Lishui City, Zhejiang Province, and to describe the actual implementation status of the diagnosis-and-treatment subsidy policy and explore associations between subsidy indicators and patient treatment outcomes.

Methods

We conducted a retrospective survey of 117 MDR/RR-TB patients diagnosed and managed in Lishui City from 2017 to 2022. Data on sociodemographic characteristics, diagnosis and treatment processes, medical expenses, and subsidy information were collected and analyzed using questionnaires.

Results

The median direct medical expenses (DME) for the 117 patients were Chinese yuan (RMB) 65,182.66 (1 RMB = 0.14 USD). The median amount reimbursed by medical insurance was RMB 40,223.33, and the median out-of-pocket (OOP) payments after medical insurance reimbursement were RMB 21,938.82. The median subsidy amount was RMB 14,405.45, resulting in final OOP payments of RMB 8,167.13. Patients using bedaquiline, linezolid, and clofazimine received higher subsidies compared to non-users (P < 0.05). Logistic regression analysis showed that subsidy amounts below RMB 14,405.45 were significantly associated with adverse treatment outcomes (95%CI: 0.046–0.534, OR = 0.157, P = 0.003). The overall treatment success rate was 75.21%.

Conclusion

MDR/RR-TB patients face a significant economic burden. The findings suggest that the subsidy policy may contribute to reducing out-of-pocket expenditures among MDR/RR-TB patients; however, further studies using stronger analytical designs are needed to evaluate its effectiveness. Optimizing subsidy criteria, raising subsidy levels and streamlining reimbursement procedures may help relieve patient financial stress, yet relevant benefits require verification via high-quality research.